Impaired skeletal health in patients with chronic atrophic gastritis

References

• Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nature reviews. Gastroenterol Hepatol. 2013;10:529–541.
   Web of Science ®Google Scholar
• Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion – clinical perspectives. Acta Physiol. 2014;210:239–256.
   PubMed Web of Science ®Google Scholar
• Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996;156:1097–1100.
   PubMedGoogle Scholar
• Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–326.
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953.
   PubMed Web of Science ®Google Scholar
• Goerss JB, Kim CH, Atkinson EJ, et al. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7:573–579.
   PubMed Web of Science ®Google Scholar
• Merriman NA, Putt ME, Metz DC, et al. Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology. 2010;138:1330–1337.
   PubMed Web of Science ®Google Scholar
• Ozdil K, Kahraman R, Sahin A, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33:2255–2260.
   PubMed Web of Science ®Google Scholar
• Eastell R, Vieira NE, Yergey AL, et al. Pernicious anaemia as a risk factor for osteoporosis. Clin Sci. 1992;82:681–685.
   PubMed Web of Science ®Google Scholar
• Bahtiri E, Islami H, Hoxha R, et al. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab. 2015. [Epub ahead of print]. doi: 10.1007/s00774-015-0699-6.
   PubMedGoogle Scholar
• Kakehasi AM, Rodrigues CB, Carvalho AV, et al. Chronic gastritis and bone mineral density in women. Dig Dis Sci. 2009;54:819–824.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2015;30:232–239.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896–904.
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol. 1985;20:569–576.
   PubMed Web of Science ®Google Scholar
• Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. Rev Sci Instrum. 2012;83:044301.
   Web of Science ®Google Scholar
• Mizuno S, Matsui D, Watanabe I, et al. Serologically determined gastric mucosal condition is a predictive factor for osteoporosis in Japanese men. Dig Dis Sci. 2015;60:2063–2069.
   PubMed Web of Science ®Google Scholar
• Kim HW, Kim YH, Han K, et al. Atrophic gastritis: a related factor for osteoporosis in elderly women. PLoS One. 2014;9:e101852.
   PubMed Web of Science ®Google Scholar
• Hans D, Goertzen AL, Krieg MA, et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26:2762–2769.
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Vestergaard P. Management of endocrine disease: diabetes and osteoporosis: cause for concern? Eur J Endocrinol. 2015;173:R93–R99.
   PubMed Web of Science ®Google Scholar
• Reppe S, Noer A, Grimholt RM, et al. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J Bone Miner Res. 2015;30:249–256.
   PubMed Web of Science ®Google Scholar
• O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–781.
   PubMed Web of Science ®Google Scholar
• Schinke T, Schilling AF, Baranowsky A, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009;15:674–681.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Stunes AK, Petzold C, et al. Decreased bone mineral density and reduced bone quality in H(+) /K(+) ATPase beta-subunit deficient mice. J Cell Biochem. 2012;113:141–147.
   PubMed Web of Science ®Google Scholar
• Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2013;62:518–526.
   PubMed Web of Science ®Google Scholar
• Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–442.
   PubMed Web of Science ®Google Scholar
• Selking O, Borch K, Johansson H, et al. Evaluation of parathyroid function in patients with hypergastrinaemia and pernicious anaemia. Ups J Med Sci. 1982;87:215–222.
   PubMed Web of Science ®Google Scholar
• Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–73.
   PubMed Web of Science ®Google Scholar
• Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25:2205–2211.
   PubMed Web of Science ®Google Scholar
• Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. 2009;28:131–141.
   PubMed Web of Science ®Google Scholar
• Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015;66:775–782.
   PubMed Web of Science ®Google Scholar
• Aasarød KM, Koldeh MR, Mosti MP, et al. 2014. Abstract. Effects of the gastrin receptor antagonist netazepide on bone quality in H+/K + ATPase beta-subunit deficient mice. In European Calcified Tissue Society Conference: Bone Abstracts (2014); 3 OC3.6.
   Google Scholar
• Deyama Y, Kikuiri T, Ohnishi G, et al. Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. Biochem Biophys Res Commun. 2002;298:240–246.
   PubMed Web of Science ®Google Scholar
• Ikawa Y, Yonekawa T, Ohkuni Y, et al. A comparative study of histamine activities on differentiation of osteoblasts and osteoclasts. J Toxicol Sci. 2007;32:555–564.
   PubMedGoogle Scholar
• Abrahamsen B, Vestergaard P. Proton pump inhibitor use and fracture risk – effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. Bone. 2013;57:269–271.
   PubMed Web of Science ®Google Scholar
• Kinjo M, Setoguchi S, Solomon DH. Antihistamine therapy and bone mineral density: analysis in a population-based US sample. Am J Med. 2008;121:1085–1091.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Lenti MV, Giuffrida P, et al. New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract. Autoimmun Rev. 2015;14:1161–1169.
   PubMed Web of Science ®Google Scholar
• Foster SC, Daniels C, Bourdette DN, et al. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol. 2003;140:78–87.
   PubMed Web of Science ®Google Scholar
• Bini EI, D’Attilio L, Marquina-Castillo B, et al. The implication of pro-inflammatory cytokines in the impaired production of gonadal androgens by patients with pulmonary tuberculosis. Tuberculosis (Edinburgh, Scotland). 2015;95:701–706.
   PubMed Web of Science ®Google Scholar
• Mealy K, Robinson B, Millette CF, et al. The testicular effects of tumor necrosis factor. Ann Surg. 1990;211:470–475.
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–931.
   PubMed Web of Science ®Google Scholar
• Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–3661.
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987;106:354–361.
   PubMed Web of Science ®Google Scholar
• Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181–186.
   PubMed Web of Science ®Google Scholar
• Sinnesael M, Boonen S, Claessens F, et al. Testosterone and the male skeleton: a dual mode of action. J Osteoporos. 2011;2011:240328.
   PubMedGoogle Scholar
• Herrmann M, Schmidt J, Umanskaya N, et al. Stimulation of osteoclast activity by low B-vitamin concentrations. Bone. 2007;41:584–591.
   PubMed Web of Science ®Google Scholar
• Vaes BL, Lute C, Blom HJ, et al. Vitamin B(12) deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid. Calcif Tissue Int. 2009;84:413–422.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Tanaka S, Saito M, et al. Plasma level of homocysteine associated with severe vertebral fracture in postmenopausal women. Calcif Tissue Int. 2013;93:269–275.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Koh JM, Ahn SH, et al. High serum total homocysteine levels accelerate hip bone loss in healthy premenopausal women and men. Bone. 2013;52:56–62.
   PubMed Web of Science ®Google Scholar
• Garton M, Reid I, Loveridge N, et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol. 1994;41:747–755.
   PubMed Web of Science ®Google Scholar
• Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys. 2010;503:129–136.
   PubMed Web of Science ®Google Scholar
• Walsh JS, Newman C, Eastell R. Heart drugs that affect bone. Trends Endocrinol Metab. 2012;23:163–168.
   PubMed Web of Science ®Google Scholar